Online inquiry

IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5590MR)

This product GTTS-WQ5590MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5590MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ836MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ7276MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ15152MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ15344MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ3927MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ14073MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ9761MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JS001
GTTS-WQ10712MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA M-1095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW